Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719862 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 481
- Enrollment target
NCT00719862: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00719862 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 481 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719862, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 481 participants
- Enrollment target
Study Summary
The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone
Primary Outcome
reflective total nasal symptom score consisting of runny nose, itchy nose, nasal congestion, and sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. Total possible score is 24 per day. Least square means was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, treatment by-study day interaction, and basline as a covariate.
Interventions
- DRUG Placebo nasal spray
- DRUG 0.15% azelastine hydrochloride Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00719862 record still lists
NCT00719862 is an interventional study that assigns participants to a tested intervention. The registered 481 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT00719862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00719862 about?
NCT00719862 is a clinical study titled "A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone
What is the current status of trial NCT00719862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 481 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00719862?
The interventions under investigation include: Placebo nasal spray (DRUG), 0.15% azelastine hydrochloride Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT00719862?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00719862's enrollment target sits among peer trials
481 792nd of 2000 higher than 1,209 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia